Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates

Fineline Cube Jan 8, 2024

Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing...

Company Deals

Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China

Fineline Cube Jan 8, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Nod for SGLT-2 Inhibitor and Metformin Combo for Type 2 Diabetes

Fineline Cube Jan 8, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...

Company Medical Device

MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China

Fineline Cube Jan 8, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Company Deals

Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach

Fineline Cube Jan 8, 2024

Ningbo Linstant Polymer Materials Co., Ltd, a Chinese manufacturer specializing in polymer accessories for medical...

Company Deals

Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases

Fineline Cube Jan 8, 2024

Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into...

Company Deals

OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC

Fineline Cube Jan 8, 2024

OnCusp Therapeutics, a U.S.-based biopharmaceutical company, has closed an oversubscribed Series A financing round, raising...

Company Deals

Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential

Fineline Cube Jan 5, 2024

Germany-based Merck (NYSE: MRK) has in-licensed the potential first-in-class candidate ompenaclid from U.S. firm Inspirna,...

Company Deals

Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies

Fineline Cube Jan 5, 2024

German pharmaceutical leader Boehringer Ingelheim (BI) has entered into a new agreement with U.S.-based 3T...

Company Deals

Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances

Fineline Cube Jan 5, 2024

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) is advancing its U.S. partnerships by joining forces...

Company Deals

Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate

Fineline Cube Jan 5, 2024

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics, has entered an exclusive license agreement with...

Company Drug

Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis

Fineline Cube Jan 5, 2024

Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443), a biopharmaceutical company based in China, has submitted...

Policy / Regulatory

Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate

Fineline Cube Jan 5, 2024

The Shanghai Administration for Market Regulation (AMR) bureau has once again reprimanded SHP No.1 Biomedical...

Company Drug

Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment

Fineline Cube Jan 5, 2024

Akeso Biopharma (HKG: 9926), a leading biopharmaceutical company based in China, has announced the submission...

Company Drug

JW Therapeutics Secures NMPA Review for CAR-T Therapy in Mantle Cell Lymphoma

Fineline Cube Jan 5, 2024

JW Therapeutics (HKG: 2126), a Chinese biopharmaceutical company, has announced that it has submitted an...

Hospital Policy / Regulatory

China’s Ministry of Education Launches Professional Guidelines for Healthcare Talent Training

Fineline Cube Jan 5, 2024

The Ministry of Education (MoE) in China has issued a Notice outlining the “Professional Guidelines...

Company Drug

Jiangsu Hengrui Pharmaceuticals Advances Novel Cancer Therapies with NMPA Clinical Trial Approval

Fineline Cube Jan 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...

Company Deals

Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round

Fineline Cube Jan 5, 2024

Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...

Company Drug

Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist

Fineline Cube Jan 5, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...

Company Deals

Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor

Fineline Cube Jan 5, 2024

China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...

Posts pagination

1 … 471 472 473 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.